ArticleJBMR plus2025

Administration and cancer-control outcomes of bone-modifying agents in real-world patients with metastatic castration-resistant prostate cancer.

Mike Wenzel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.